Niagen Bioscience (NAGE) Change in Accured Expenses (2011 - 2026)

Niagen Bioscience (NAGE) has 15 years of Change in Accured Expenses data on file, last reported at -$101000.0 in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 108.19% year-over-year to -$101000.0 in Q1 2026; TTM through Mar 2026 was $507000.0, a 65.44% decrease from a year earlier, with the FY2025 full-year figure at $1.8 million, up 52.65% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$101000.0, down from $958000.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for NAGE reached as high as $1.6 million in Q1 2022 and fell as low as -$1.8 million in Q2 2024.
• Historically, Change in Accured Expenses has averaged $350470.6 across 5 years, with a median of $958000.0 in 2025.
• Across the five-year window, Change in Accured Expenses soared 1756.67% in 2023 and tumbled 247.27% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $581000.0 in 2022, then tumbled by 48.36% to $300000.0 in 2023, then surged by 269.0% to $1.1 million in 2024, then fell by 13.46% to $958000.0 in 2025, then tumbled by 110.54% to -$101000.0 in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$101000.0 in Q1 2026, $958000.0 in Q4 2025, and $1.3 million in Q3 2025.